

# Fred R Hirsch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5690856/publications.pdf>

Version: 2024-02-01

156  
papers

17,459  
citations

38742

50  
h-index

15266

126  
g-index

158  
all docs

158  
docs citations

158  
times ranked

18979  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. <i>Clinical Lung Cancer</i> , 2022, 23, 21-33.	2.6	12
2	EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. <i>Clinical Lung Cancer</i> , 2022, 23, 60-71.	2.6	5
3	Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. <i>Journal of Thoracic Oncology</i> , 2022, 17, 214-227.	1.1	26
4	Loss of STING expression is prognostic in non-small cell lung cancer. <i>Journal of Surgical Oncology</i> , 2022, 125, 1042-1052.	1.7	8
5	Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100269.	1.1	0
6	Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma. <i>Oncologist</i> , 2022, 27, 476-486.	3.7	15
7	International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2022, , .	1.1	4
8	Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer. <i>Cancer Cell</i> , 2022, 40, 575-577.	16.8	11
9	Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study. <i>Journal of Pathology</i> , 2022, 257, 674-686.	4.5	26
10	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	5
11	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16
12	Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	8.6	39
13	A phase 1b/2 trial of dupilumab given in conjunction with PD-(L)1 blockade in the treatment of relapsed/refractory metastatic NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9139-TPS9139.	1.6	2
14	Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403). <i>Clinical Cancer Research</i> , 2022, 28, 3752-3760.	7.0	18
15	A Phase II Study of Telisotuzumab Vedotin in Patients With MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). <i>Clinical Lung Cancer</i> , 2021, 22, 170-177.	2.6	41
16	Where are we with proton beam therapy for thoracic malignancies? Current status and future perspectives. <i>Lung Cancer</i> , 2021, 152, 157-164.	2.0	6
17	The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 1029-1038.	2.8	12
18	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	27.6	646

#	ARTICLE	IF	CITATIONS
19	Abstract S01-02: Assessing vulnerability of patients with lung cancer to SARS-CoV-2 infection based on serological antibody analyses. , 2021, , .		0
20	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. Journal of Thoracic Oncology, 2021, 16, 686-696.	1.1	13
21	KRAS G12Câ€“Mutant Nonâ€“Small Cell Lung Cancer. Journal of Molecular Diagnostics, 2021, 23, 507-520.	2.8	40
22	Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. Oncologist, 2021, 26, e1226-e1239.	3.7	17
23	Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repairâ€“Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clinical Lung Cancer, 2021, 22, 187-194.e1.	2.6	18
24	Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis. Lung Cancer, 2021, 156, 59-67.	2.0	7
25	The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities. Journal of Thoracic Oncology, 2021, 16, 897-901.	1.1	8
26	Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and -Low Small Cell Lung Cancer. Biology, 2021, 10, 502.	2.8	21
27	Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse. Translational Lung Cancer Research, 2021, 10, 2452-2474.	2.8	11
28	The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients. Clinical Lung Cancer, 2021, , .	2.6	4
29	CCL19 associates with lymph node metastasis and inferior prognosis in patients with small cell lung cancer. Lung Cancer, 2021, 162, 194-202.	2.0	5
30	Assessing the association of diabetes with lung cancer risk. Translational Lung Cancer Research, 2021, 10, 4200-4208.	2.8	9
31	â€œInterchangeabilityâ€œof PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Modern Pathology, 2020, 33, 4-17.	5.5	135
32	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. Journal of Thoracic Oncology, 2020, 15, 29-49.	1.1	106
33	Treatment of spine metastases in cancer: a review. Journal of International Medical Research, 2020, 48, 030006051988810.	1.0	6
34	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 499-519.	1.1	203
35	Programmed Cell Death Ligand 1 Expression in Resected Nonâ€“Small Cell Lung Cancer. Clinical Lung Cancer, 2020, 22, e555-e562.	2.6	1
36	Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). Journal of Thoracic Oncology, 2020, 15, 1748-1757.	1.1	21

#	ARTICLE	IF	CITATIONS
37	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	1.1	182
38	Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution. <i>Molecular Oncology</i> , 2020, 14, 1947-1965.	4.6	48
39	Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2020, 11, 551-558.	2.5	7
40	Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9576-9576.	1.6	1
41	SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9623-9623.	1.6	0
42	Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9532-9532.	1.6	7
43	EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis. <i>Cancer Treatment Reviews</i> , 2019, 72, 15-27.	7.7	37
44	Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1704-1717.	1.1	8
45	The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1172-1183.	1.1	60
46	Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer. <i>Respiratory Research</i> , 2019, 20, 248.	3.6	12
47	Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, 559-574.	2.8	5
48	Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee and International Association for the Study of Lung Cancer and Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1718-1731.	1.1	15
49	Galectin-9 in non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 136, 80-85.	2.0	32
50	OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. <i>Translational Lung Cancer Research</i> , 2019, 8, 352-366.	2.8	38
51	Frequency and significance of epidermal growth factor receptor mutations detected by PCR methods in patients with non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 5125-5131.	1.8	6
52	Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions. <i>Clinical Lung Cancer</i> , 2019, 20, e517-e530.	2.6	19
53	Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 72.	5.0	24
54	c-MET as a biomarker in patients with surgically resected non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 133, 69-74.	2.0	22

#	ARTICLE	IF	CITATIONS
55	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 377-407.	1.1	212
56	Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 630-643.	3.4	217
57	Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases. <i>Translational Lung Cancer Research</i> , 2019, 8, 938-950.	2.8	13
58	Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib. <i>Clinical Lung Cancer</i> , 2019, 20, e39-e51.	2.6	11
59	EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases. <i>International Journal of Cancer</i> , 2019, 144, 2605-2612.	5.1	30
60	Risk factors for nicotine dependence in Chinese patients with lung cancer. <i>Journal of International Medical Research</i> , 2019, 47, 391-397.	1.0	1
61	T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 895-906.	2.8	29
62	Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. <i>Clinical Lung Cancer</i> , 2018, 19, e421-e430.	2.6	53
63	EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism. <i>Lung Cancer</i> , 2018, 120, 82-87.	2.0	11
64	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 323-358.	1.1	408
65	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 321-346.	2.5	586
66	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 129-159.	2.8	241
67	Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. <i>Journal of Thoracic Oncology</i> , 2018, 13, 205-217.	1.1	33
68	EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. <i>Journal of Thoracic Oncology</i> , 2018, 13, 228-236.	1.1	14
69	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 853-861.e4.	16.8	725
70	Physician Bias in Prophylactic Cranial Irradiation Decision Making—An Opportunity for a Patient Decision Aid. <i>Clinical Lung Cancer</i> , 2018, 19, 476-483.	2.6	3
71	Genomic Testing in Lung Cancer: Past, Present, and Future. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 323-334.	4.9	20
72	Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-Cell Lung Cancer: SWOG S0635 and S0636 Trials. <i>Clinical Lung Cancer</i> , 2018, 19, 84-92.	2.6	7

#	ARTICLE	IF	CITATIONS
73	Early detection of lung cancer by using an autoantibody panel in Chinese population. <i>OncolImmunology</i> , 2018, 7, e1384108.	4.6	54
74	Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 101-114.	10.7	62
75	PACIFIC trial: new perspectives for immunotherapy in lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S19-S24.	2.8	2
76	The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. <i>Lung Cancer</i> , 2018, 125, 115-120.	2.0	29
77	Serum microRNAs improving the diagnostic accuracy in lung cancer presenting with pulmonary nodules. <i>Journal of Thoracic Disease</i> , 2018, 10, 5080-5085.	1.4	18
78	TIM-3, a promising target for cancer immunotherapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7005-7009.	2.0	172
79	sLAG-3 in non-small-cell lung cancer patients&rsquo; serum. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4781-4784.	2.0	25
80	A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. <i>Clinical Lung Cancer</i> , 2018, 19, 450-456.	2.6	4
81	Innate Genetic Evolution of Lung Cancers and&Aacute;Spatial Heterogeneity: Analysis of Treatment-Na&Atilde;ve Lesions. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1496-1507.	1.1	22
82	Liquid Biopsy for Advanced Non-Small Cell Lung&Aacute;Cancer (NSCLC): A Statement Paper from the&Aacute;IASLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1248-1268.	1.1	515
83	CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2257-2265.	4.1	41
84	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1302-1311.	1.1	589
85	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)., 2018, 6, 75.		188
86	Heterogeneity in Immune Marker Expression after&Aacute;Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung&Aacute;Cancer Transformation. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1015-1020.	1.1	20
87	A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non&Aacute;Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1051.	7.1	658
88	LAG-3 Protein Expression in Non&Aacute;Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. <i>Journal of Thoracic Oncology</i> , 2017, 12, 814-823.	1.1	192
89	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. <i>Lung Cancer</i> , 2017, 109, 1-8.	2.0	27
90	PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. <i>Journal of Thoracic Oncology</i> , 2017, 12, 208-222.	1.1	1,067

#	ARTICLE	IF	CITATIONS
91	Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 640-650.e2.	2.6	5
92	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209.	1.1	40
93	MHC class II expression in lung cancer. <i>Lung Cancer</i> , 2017, 112, 75-80.	2.0	80
94	Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1388-1397.	1.1	49
95	Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 779-786.	2.4	27
96	Lung cancer: current therapies and new targeted treatments. <i>Lancet, The</i> , 2017, 389, 299-311.	13.7	2,267
97	Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 43-49.	2.6	31
98	PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 110-120.	1.1	108
99	Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. <i>Journal of Thoracic Oncology</i> , 2017, 12, 27-35.	1.1	24
100	Biomarker Testing for Personalized Therapy in Lung Cancer in Low- and Middle-Income Countries. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 403-408.	3.8	11
101	Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. <i>Theranostics</i> , 2017, 7, 4753-4762.	10.0	25
102	Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. <i>BioMed Research International</i> , 2017, 2017, 1-7.	1.9	13
103	Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5915-5926.	2.0	15
104	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. <i>Medical Science Monitor</i> , 2017, 23, 1208-1216.	1.1	49
105	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. <i>JCI Insight</i> , 2017, 2, e90449.	5.0	45
106	Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. <i>PLoS ONE</i> , 2017, 12, e0172209.	2.5	13
107	Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases. <i>OncoTargets and Therapy</i> , 2016, 9, 2409.	2.0	3
108	Clinical potential of necitumumab in non-small cell lung carcinoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5427-5437.	2.0	21

#	ARTICLE	IF	CITATIONS
109	Heterogeneity in Tumors and Resistance to EGFR TKI Therapy”Letter. <i>Cancer Research</i> , 2016, 76, 3109-3110.	0.9	6
110	PD-L1 Expression in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 964-975.	1.1	329
111	cMET Exon 14 Skipping: From the Structure to the Clinic. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1423-1432.	1.1	51
112	Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1711-1717.	1.1	12
113	Lymphocyte”activation gene”3, an important immune checkpoint in cancer. <i>Cancer Science</i> , 2016, 107, 1193-1197.	3.9	168
114	New and emerging targeted treatments in advanced non-small-cell lung cancer. <i>Lancet, The</i> , 2016, 388, 1012-1024.	13.7	381
115	Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma. <i>Cancer Prevention Research</i> , 2016, 9, 96-104.	1.5	34
116	Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy. <i>Journal of Clinical Neuroscience</i> , 2016, 26, 46-49.	1.5	12
117	Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 326-331.	2.5	118
118	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	1.1	156
119	From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2016, 11, 287-299.	1.1	45
120	Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma. <i>Medical Science Monitor</i> , 2016, 22, 276-283.	1.1	17
121	Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?. <i>Journal of Thoracic Oncology</i> , 2015, 10, 985-989.	1.1	241
122	PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1364-1369.	1.1	16
123	Three”arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non”small cell lung cancer (NSCLC) patients who will not receive bevacizumab”based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). <i>Cancer</i> , 2015, 121, 2253-2261.	4.1	21
124	Long non-coding RNA <i>UCA1</i> induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in <i>EGFR</i> -mutant non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 23582-23593.	1.8	144
125	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2015, 16, 763-774.	10.7	431
126	FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 4356-4364.	7.0	75



#	ARTICLE	IF	CITATIONS
127	ROS1 Immunohistochemistry Among Major Genotypes of Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 106-111.	2.6	54
128	Lung Master Protocol (Lung-MAP) – A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. <i>Clinical Cancer Research</i> , 2015, 21, 1514-1524.	7.0	205
129	Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial. <i>Lung Cancer</i> , 2015, 88, 223-230.	2.0	23
130	Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer. <i>Oncologist</i> , 2015, 20, 316-322.	3.7	151
131	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 328-337.	10.7	124
132	Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3701-3709.	1.6	129
133	Independent validation test of the vote-counting strategy used to rank biomarkers from published studies. <i>Biomarkers in Medicine</i> , 2015, 9, 751-761.	1.4	25
134	Adjuvant TKIs in NSCLC: what can we learn from RADIANT?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 689-690.	27.6	5
135	FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies. <i>Clinical Cancer Research</i> , 2014, 20, 3299-3309.	7.0	141
136	Companion Diagnostics – Has Their Time Come and Gone?. <i>Clinical Cancer Research</i> , 2014, 20, 4422-4424.	7.0	18
137	MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. <i>Oncotarget</i> , 2014, 5, 7902-7916.	1.8	57
138	Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non-Small-Cell Lung Cancer: SWOG S0536. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1519-1528.	1.1	22
139	Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012. <i>Journal of Thoracic Oncology</i> , 2013, 8, 373-384.	1.1	113
140	Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819. <i>Clinical Cancer Research</i> , 2012, 18, 4004-4012.	7.0	45
141	A Dramatic Response to Crizotinib in a Non-Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK. <i>Journal of Thoracic Oncology</i> , 2012, 7, e36-e38.	1.1	87
142	EGFR expression and the flexibility of FLEX. <i>Lancet Oncology</i> , The, 2012, 13, 3-5.	10.7	0
143	Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non-Small-Cell Lung Cancer: Southwest Oncology Group Study S0342. <i>Journal of Clinical Oncology</i> , 2010, 28, 4747-4754.	1.6	66
144	Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non-Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 3351-3357.	1.6	278

#	ARTICLE	IF	CITATIONS
145	First-Generation Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer: Clinical Impact of the Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization Assay. <i>Journal of Thoracic Oncology</i> , 2008, 3, S138-S142.	1.1	10
146	Biological Markers for Non-Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2006, 12, 3652-3656.	7.0	62
147	Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. <i>Current Opinion in Oncology</i> , 2005, 17, 118-122.	2.4	60
148	Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 6838-6845.	1.6	574
149	The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. <i>Seminars in Oncology</i> , 2004, 31, 75-82.	2.2	56
150	Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. <i>Lung Cancer</i> , 2003, 41, 29-42.	2.0	189
151	Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis. <i>Journal of Clinical Oncology</i> , 2003, 21, 3798-3807.	1.6	1,333
152	Future developments in the treatment of lung cancer. <i>Lung Cancer</i> , 2002, 38, 81-85.	2.0	6
153	HER2/neu expression in malignant lung tumors. <i>Seminars in Oncology</i> , 2002, 29, 51-58.	2.2	92
154	Expression of target molecules in lung cancer: Challenge for a new treatment paradigm. <i>Seminars in Oncology</i> , 2002, 29, 2-8.	2.2	9
155	Review of Recent Advances in Fluorescence Bronchoscopy in Early Localization of Central Airway Lung Cancer. <i>Oncologist</i> , 2001, 6, 257-262.	3.7	83
156	Longitudinal COVID-19 Vaccination-Induced Antibody Responses and Omicron Neutralization in Patients With Lung Cancer. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	2